Skip to content
LIVE
The Executives BriefThe Executives Brief

The fix for Zepbound's muscle problem isn't a drug. It's the gym

A new study finds Zepbound users who train consistently can still get stronger even as the drug takes some muscle, reframing the lean-mass fight for Lilly, payers and patients.

ByKhalid Al-HarbiBusiness Desk, The Executives Brief
·4 min read
The fix for Zepbound's muscle problem isn't a drug. It's the gym
Executive summary

A new study found that people taking Eli Lilly's Zepbound who engage in consistent resistance training can still get stronger even if they lose some of their muscle. For decision-makers in pharma, employer health plans and the fitness economy, the finding turns the loudest critique of GLP-1 drugs into an argument for the behavioral program wrapped around them.

The loudest criticism of weight-loss drugs just got a partial rebuttal, and it does not come in a syringe. A new study found that people taking Zepbound who engage in consistent resistance training can still get stronger even if they lose some of their muscle. Read that again, because it separates two things the public debate has been fusing together for two years: how much muscle you have, and what that muscle can actually do. The study does not claim the drug spares lean mass. It claims strength is not an automatic casualty of the weight loss, provided the person doing the lifting is consistent about it. That is a narrower claim than the headlines will suggest, and a more useful one.

Zepbound is Eli Lilly's brand of tirzepatide, part of the GLP-1 class that has rewritten the economics of obesity treatment and, increasingly, the daily habits of millions of patients. From the moment these drugs went mainstream, one critique followed them everywhere: that rapid weight loss strips away lean tissue along with fat, leaving patients lighter but physically diminished. That concern is not fringe. Clinicians have long worried about muscle loss during any fast, large-scale weight reduction, and the fear has shaped how some patients and prescribers think about staying on treatment at all. The new finding chips at the strongest version of that fear. If someone on Zepbound can add strength while shedding weight, then the "lighter but weaker" story is not the whole story, and possibly not the typical one for people who train.

What the study does not do is declare the muscle question settled. Strength and muscle mass are related but not identical, and that distinction matters enormously here. You can lose some tissue and still improve how much you can lift or how well your body performs, especially when you are training a system that was previously untrained. That is roughly the mechanism at work: resistance training gives the body a reason to hold onto and improve the function of what remains. Nor does the research suggest the drug itself builds muscle, or that skipping the gym and taking the shot produces the same result. The active ingredient in the finding is the training. The drug is the context in which it happens.

That framing carries commercial weight. Lilly and Novo Nordisk have built enormous franchises on this drug class, and the muscle-loss narrative has been one of the few arguments that genuinely troubles the growth story. It has been picked up by skeptics, by compounding pharmacies selling alternatives, and by employers and insurers hunting for reasons to slow coverage down. Every headline about patients losing lean mass lands as a question about whether the weight people are losing is the right kind of weight. A study showing that consistent lifters get stronger reframes the debate from "does this drug damage your body" to "what has to accompany this drug," which is a far friendlier question for the companies selling it and a far more actionable one for everyone else.

For patients and the clinicians managing them, the practical implication is unglamorous: resistance training is the lever. Standard weight-management guidance has historically paired strength work with adequate protein intake during periods of caloric deficit, precisely to protect lean tissue. What is new here is evidence that the same logic holds inside a drug-driven weight loss program, where appetite suppression can make it harder to eat enough and the pounds can come off fast. That is a prescription no pharmacy fills, and it is exactly the kind of thing that gets skipped when a patient's entire interaction with the health system is a monthly refill.

The second-order effects run well beyond the clinic. A drug class this large, with users chasing a specific and measurable physical goal of keeping muscle while losing fat, creates demand for the services that measure and serve it: gyms and personal trainers, body-composition scanning, wearable and app-based strength tracking, and the digital platforms already built around prescribing and monitoring GLP-1 patients. Employer benefits teams, which have spent the past two years wrestling with the cost and the long-term value of covering these drugs, now have a concrete, low-tech intervention they can attach to coverage. None of that requires a new molecule. It requires a program.

The strategic stakes differ by seat at the table. For pharma, the competitive edge may increasingly sit less in the molecule than in the behavioral scaffolding around it, because the company that can credibly promise "lighter and stronger" sells a better outcome than the one promising weight loss alone. For payers and employers, the study offers a way to think about coverage as an investment in a program rather than a recurring bill with no measurable return. For anyone building in fitness, nutrition or digital health, it is a signal that the fastest-growing patient population in decades has a problem that dumbbells and coaching can address.

What to watch next is whether the strength finding holds up across the rest of the class, and whether it changes what clinicians actually tell patients on day one. The honest summary of the study is modest and important at the same time: the drug takes some muscle, and consistent training can still make you stronger anyway. That is not a cure for the lean-mass critique. It is the first credible answer to it, and it points somewhere uncomfortable for anyone who wanted a simple verdict on these drugs, which is that the shot was never doing the whole job.

Executive ActionsLocked

This story's Key Insights and Take-aways are locked.

Create a free account to unlock Executive Actions for one credit.

Register to Unlock

Always free for Executives Club members. Join the Club

More in Science